Home Cancer Genetics and Molecular Tumor Testing FLT3 Mutation Test: AML, Leukemia Risk, and Treatment Results

FLT3 Mutation Test: AML, Leukemia Risk, and Treatment Results

By
Vita Library
-
34
Learn how the FLT3 mutation test guides AML risk assessment, targeted treatment, transplant planning, relapse testing, and interpretation of ITD and TKD results.

An FLT3 mutation test checks leukemia cells for changes in the FMS-like tyrosine kinase 3 gene. It is a standard part of evaluating newly diagnosed acute myeloid leukemia because a positive result can affect risk assessment and the choice of a targeted FLT3 inhibitor. The two main findings are internal tandem duplications, called FLT3-ITD, and tyrosine kinase domain mutations, called FLT3-TKD. Testing is usually performed on bone marrow or blood containing leukemia blasts, and rapid results may be needed before induction treatment begins. FLT3 status can change over time, so clinicians commonly retest at relapse or refractory disease even when the original result was negative. A positive test does not define prognosis by itself; age, chromosome findings, NPM1 status, measurable residual disease, treatment response, and transplant options all contribute. The report should identify the mutation type, testing method, detection limit, and whether the finding meets criteria for a specific drug or clinical trial.

  • FLT3 testing should be performed promptly in newly diagnosed AML because the result can change initial treatment.
  • FLT3-ITD is generally linked to a higher relapse risk, but modern risk classification also considers NPM1, other genetics, and treatment response.
  • FLT3-TKD is biologically different from FLT3-ITD, and its prognostic effect is less consistent.
  • A negative result at diagnosis does not rule out a later FLT3-positive relapse, so repeat testing is important when AML returns or resists treatment.
  • FLT3 inhibitors are used in several settings, including selected newly diagnosed, relapsed or refractory, and post-transplant situations.

Table of Contents

What FLT3 testing detects

FLT3 encodes a receptor tyrosine kinase found on early blood-forming cells. Under normal conditions, binding of FLT3 ligand helps regulate cell survival, growth, and maturation. An activating mutation can keep the receptor signaling without normal control, allowing an AML clone to expand.

About one-quarter to one-third of adults with newly diagnosed AML have an FLT3 alteration, although frequency varies by age and leukemia subtype. The test mainly looks for two groups.

FLT3 internal tandem duplication

FLT3-ITD is a duplicated stretch of DNA inserted within the gene, usually in the juxtamembrane region. The insertion length and precise site differ among patients. The altered receptor signals continuously through pathways that promote leukemia-cell proliferation and survival.

Historically, laboratories reported an allelic ratio, comparing the amount of mutant FLT3-ITD with the normal allele. Older risk systems used high versus low ratios, especially with NPM1 status. Current European LeukemiaNet classification no longer uses the FLT3-ITD allelic ratio to assign AML genetic risk. Testing reports may still include it, and the amount of mutant disease can provide context, but it should not be interpreted through outdated cutoffs without specialist review.

FLT3-ITD is associated with leukocytosis, a higher chance of relapse, and clonal instability. The adverse effect is modified by co-occurring genetics, measurable residual disease, use of FLT3 inhibitors, and allogeneic transplant. It is therefore inaccurate to tell every FLT3-ITD-positive person that the outlook is uniformly poor.

FLT3 tyrosine kinase domain mutations

FLT3-TKD mutations usually affect codon D835 or the nearby activation loop, although other changes occur. They also activate the receptor but differ from ITD mutations in biology, drug sensitivity, and resistance patterns. Their independent effect on prognosis is less consistent.

Some TKD mutations are present at diagnosis. Others emerge after treatment with an FLT3 inhibitor, particularly an inhibitor that does not suppress that mutant form. The exact amino-acid change matters because drugs bind different receptor conformations.

A person may have both FLT3-ITD and FLT3-TKD, multiple ITD clones, or an FLT3 alteration alongside NPM1, DNMT3A, IDH1, IDH2, RAS-pathway, or other mutations. AML is therefore best assessed with a broader myeloid panel rather than treating FLT3 as the only molecular result. Related NPM1 mutation testing is especially important for classification, prognosis, and molecular residual-disease monitoring.

FLT3 mutations in AML are usually somatic, meaning they arose in the leukemia cells and are not inherited by children. Germline FLT3 variants are not a common hereditary AML syndrome. The result generally does not require predictive testing of healthy relatives unless another finding or family history suggests an inherited blood-cancer predisposition.

Who needs testing and when

Every patient with newly diagnosed AML should have FLT3 mutation testing as part of the initial molecular workup. The result may be needed within days because it can determine whether an FLT3 inhibitor is added to induction therapy. The laboratory and clinical team should use a rapid pathway rather than waiting for a slow broad-panel result when treatment must start urgently.

Testing is also recommended in several additional situations:

  • Relapsed AML. The leukemia may acquire FLT3-ITD or FLT3-TKD even if the original test was negative.
  • Primary refractory AML. Persistent leukemia after initial treatment should be molecularly reassessed when feasible.
  • Before an FLT3-directed salvage treatment. Current mutation status should support use of the inhibitor.
  • After progression on an FLT3 inhibitor. Repeat testing can identify on-target resistance mutations and alternative pathways.
  • Before or after allogeneic transplant in selected patients. Sensitive FLT3-ITD measurable residual disease testing may refine relapse risk and maintenance discussions.
  • At suspected lineage or disease change. A new marrow examination can determine whether the current clone matches the original leukemia.

FLT3 testing is not a general screening test for people without AML. It does not estimate a healthy person’s future leukemia risk. Symptoms such as fatigue, bruising, fever, or abnormal blood counts require a complete medical evaluation, not an isolated FLT3 assay.

The diagnosis of AML depends on blood and bone marrow morphology, flow cytometry, cytogenetics, and molecular findings. In some genetically defined subtypes, blast-count rules have changed, but FLT3 alone does not establish AML. The mutation may also occur in myelodysplastic syndromes or other myeloid neoplasms, generally at lower frequency.

Testing should be ordered alongside chromosome analysis, fluorescence in situ hybridization when indicated, and a myeloid mutation panel. Results in genes such as NPM1, CEBPA, TP53, RUNX1, ASXL1, IDH1, IDH2, and myelodysplasia-related genes affect classification and risk. A DNMT3A mutation result can represent an early founding clone and may persist in remission without indicating active AML, unlike more leukemia-specific markers.

Rapid treatment does not always mean molecular testing must be skipped. Many centers can begin supportive care, leukostasis management, or cytoreduction while awaiting a fast FLT3 result. The hematologist balances urgency, white-cell count, symptoms, and the planned regimen.

Samples, methods, and report details

Bone marrow aspirate is often the preferred specimen because it usually contains the highest concentration of leukemia blasts and is already collected for diagnosis. Peripheral blood can be suitable when circulating blasts are abundant. A blood sample with few or no blasts may produce a false-negative or underestimate the mutant level.

Several methods are used:

  • Fragment analysis by polymerase chain reaction is a common rapid method for FLT3-ITD. It amplifies the affected region and separates products by size. It can detect duplicated fragments and estimate mutant-to-wild-type signal.
  • Next-generation sequencing detects FLT3-TKD mutations and may identify ITDs, but ITD performance varies by platform and bioinformatics pipeline. Long or unusual insertions can be difficult for some assays.
  • Targeted PCR or allele-specific assays can detect common TKD changes rapidly.
  • High-sensitivity error-corrected sequencing or PCR may be used for measurable residual disease, with a detection limit far below ordinary diagnostic testing.

A broad myeloid NGS panel should clearly state whether its FLT3-ITD detection has been validated across insertion sizes and allele levels. Some laboratories pair NGS with a separate fragment assay to reduce false negatives.

The report should include:

  • specimen type and collection date;
  • percentage of blasts or tumor cells, when available;
  • FLT3-ITD, FLT3-TKD, or both;
  • exact TKD variant and ITD size or location when reported;
  • variant allele fraction or allelic ratio;
  • assay detection limit;
  • whether more than one FLT3 clone was found;
  • interpretation for the current AML setting; and
  • technical limitations.

Variant allele fraction is the percentage of sequencing reads carrying a variant. It is influenced by leukemia-cell percentage, copy number, normal-cell contamination, and clonal structure. It is not the percentage of the body affected and should not be used alone to stage leukemia.

The allelic ratio from fragment analysis is not interchangeable with NGS variant allele fraction. Different laboratories may produce different numbers from the same sample because the methods measure signals differently. Trends are most reliable when the same specimen type and validated assay are used.

Turnaround time ranges from hours or a few days for a rapid assay to one or two weeks for a broad panel. If treatment hinges on the result, the clinician should confirm that a preliminary or expedited FLT3 report will be issued.

A dry tap, hemodiluted marrow, low blast count, or degraded sample can limit testing. The report may say “not detected” even when analytic sensitivity was poor. Clinicians should distinguish a technically valid negative from an inadequate specimen.

Understanding a positive result

A positive FLT3 result confirms that an activating alteration was detected in the tested leukemia sample. It can influence drug selection and risk assessment, but it must be integrated with the entire AML profile.

For FLT3-ITD, current ELN genetic risk classification places patients in the intermediate-risk group when they do not have an adverse-risk genetic lesion, regardless of NPM1 status or allelic ratio. An adverse chromosome or molecular abnormality can still place the leukemia in the adverse category. Favorable molecular findings do not erase the clinical importance of FLT3-directed therapy.

Risk classification is a starting framework, not a personal survival prediction. Important modifiers include:

  • age and fitness for intensive treatment;
  • presenting white-cell count and organ complications;
  • chromosome findings and co-mutations;
  • speed and depth of remission;
  • measurable residual disease after induction and consolidation;
  • availability of an allogeneic donor;
  • treatment with a potent FLT3 inhibitor; and
  • whether disease is newly diagnosed or relapsed.

A positive TKD result may support a drug active against that mutation, but different inhibitors have different spectra. Type I inhibitors bind the active receptor conformation and generally inhibit both ITD and many TKD mutations. Type II inhibitors bind an inactive conformation and are usually active against ITD but can lose activity with activation-loop TKD mutations such as D835.

The report may use terms such as pathogenic, likely pathogenic, Tier I, Tier II, or clinically significant. In a somatic cancer report, these labels reflect oncogenicity and treatment evidence rather than inherited disease risk. A recurrent FLT3-ITD is clearly leukemogenic; an unusual missense variant may need deeper review before it is treated as an actionable TKD mutation.

Multiple FLT3 clones can have different allele levels. A small subclone may expand during treatment, while a dominant clone may disappear. The largest number on a report is not necessarily the only clinically relevant clone.

Co-occurring IDH1 or IDH2 mutations can create additional targeted options, especially in relapsed disease or in lower-intensity regimens. Treatment sequencing should account for the dominant biology, prior drugs, toxicities, and trial availability rather than assuming both targeted agents should be used together outside evidence-based protocols.

A positive result does not mean leukemia developed from an inherited family mutation. It also does not prove that an FLT3 inhibitor will produce remission. Resistance can be present from the start or develop through FLT3 changes, RAS/MAPK activation, altered apoptosis pathways, or protective signals from the bone marrow environment.

Negative, low-level, and changing results

A negative result means no reportable FLT3-ITD or tested TKD mutation was found above the assay’s detection limit. It does not rule out AML, and it does not mean the leukemia has a favorable prognosis. Other genetic and clinical factors remain decisive.

Reasons for an unexpected negative result include:

  • low leukemia-cell content in blood or marrow;
  • hemodilution of the marrow aspirate;
  • an ITD too long or complex for the assay;
  • coverage gaps in an NGS panel;
  • a TKD mutation outside the tested hotspots;
  • treatment before collection reducing the clone; or
  • reporting thresholds that exclude very low-level findings.

When a rapid assay and broad NGS panel disagree, the laboratory should review the methods. Fragment analysis may detect an ITD that short-read NGS misses, while NGS may identify a rare TKD variant not covered by a hotspot assay. An orthogonal test can resolve clinically important discordance.

A low-level FLT3 clone at diagnosis may still matter because treatment can select it. However, analytic artifacts are more common near the detection limit, so confirmation and correlation with other data are important. The report should indicate whether the finding meets the validated threshold for clinical use.

FLT3 is a late and unstable AML mutation compared with founding changes such as DNMT3A. It may be lost, gained, or replaced at relapse. Studies have shown that a substantial minority of patients have different FLT3 status between diagnosis and relapse. Retesting should use the current disease sample rather than relying on an old report.

A previously positive FLT3 result that becomes negative after therapy may represent a deep response, loss of the FLT3 clone, or insufficient test sensitivity. Standard diagnostic NGS is not sensitive enough for all residual-disease questions. Conversely, persistent low-level FLT3-ITD during remission may signal residual leukemia and increased relapse risk when measured by a validated high-sensitivity method.

FLT3-TKD is generally less established as a standalone measurable residual disease marker. The mutation may be absent in some relapses, and common hotspot assays may not achieve the needed sensitivity. Flow cytometry and other molecular markers often complement FLT3 testing.

A negative FLT3 MRD result does not prove cure. Sampling error, patchy marrow disease, clonal evolution, and the assay’s limit all matter. MRD should be interpreted at specified time points with morphology, blood-count recovery, and the planned transplant or maintenance strategy.

Treatment and transplant decisions

FLT3-directed therapy depends on the mutation, age, fitness, treatment phase, and local approvals. Drug names on a laboratory report are suggestions for clinical review, not prescriptions.

Newly diagnosed AML

For adults fit for intensive induction, midostaurin combined with standard chemotherapy has been a widely used option for FLT3-mutated AML, including ITD and TKD mutations. The drug is given during induction and consolidation, and treatment protocols differ regarding maintenance.

Quizartinib combined with intensive chemotherapy, followed by consolidation and continuation therapy, improved overall survival in adults aged 18 to 75 with newly diagnosed FLT3-ITD-positive AML in the QuANTUM-First trial. It is approved in defined settings for FLT3-ITD, not for FLT3-TKD alone. QT-interval monitoring and drug-interaction review are important.

People who are older or not candidates for intensive chemotherapy may receive lower-intensity regimens, often based on a hypomethylating agent plus venetoclax. FLT3 inhibitor combinations are active areas of study and are used in selected practices or trials. Myelosuppression and infection risk can be substantial with multi-drug combinations.

Relapsed or refractory AML

Gilteritinib is an established single-agent treatment for adults with relapsed or refractory AML carrying an FLT3 mutation. It has activity against ITD and several TKD mutations and improved survival compared with salvage chemotherapy in the ADMIRAL trial. Differentiation syndrome, liver abnormalities, QT prolongation, pancreatitis, and cytopenias require monitoring.

Some patients receive a targeted inhibitor as a bridge to allogeneic hematopoietic cell transplant. Others use it after transplant relapse or within a combination trial. Response can include complete remission, remission with incomplete count recovery, or meaningful blast reduction that permits transplant.

Allogeneic transplant and maintenance

Allogeneic transplant in first remission is often considered for FLT3-ITD AML because of relapse risk, but the decision depends on ELN risk, MRD, age, comorbidities, donor options, and patient preferences. Transplant is not automatically required for every FLT3-positive patient.

Post-transplant FLT3 inhibitor maintenance can reduce relapse in selected patients. Evidence supports sorafenib in several studies, and a randomized gilteritinib study showed that the clearest benefit was among patients with detectable FLT3-ITD MRD before or after transplant. Choice, timing, dose, and duration require transplant-specialist review because graft-versus-host disease, interactions, cytopenias, and organ toxicity affect feasibility.

FLT3 inhibitors can cause overlapping adverse effects, including nausea, diarrhea, rash, liver-test elevation, cytopenias, infection, and QT prolongation. Each drug has a distinct profile. Strong CYP3A inhibitors, azole antifungals, and other QT-prolonging medicines may change exposure or cardiac risk. Medication reconciliation and electrocardiographic monitoring are essential when indicated.

Monitoring and questions to ask

AML response is assessed with blood counts, bone marrow morphology, flow cytometry, cytogenetics, and molecular tests. FLT3-ITD can be monitored with high-sensitivity assays, but the laboratory must validate the method for MRD. A standard diagnostic test with a 1% or 5% detection limit cannot answer a question that requires sensitivity near one leukemia cell in 10,000 or 100,000 cells.

The timing of MRD testing commonly includes after induction, after consolidation, before transplant, and after transplant. The exact schedule depends on the treatment protocol and available markers. NPM1 is often a more stable and standardized molecular marker when present. Flow cytometry remains valuable even when a molecular marker is available.

Ask the hematology team:

  1. Was the result FLT3-ITD, FLT3-TKD, or both?
  2. Was the test performed on marrow or blood, and were enough blasts present?
  3. Does the assay reliably detect long ITDs and uncommon TKD variants?
  4. How do NPM1, chromosomes, and other mutations change my ELN risk group?
  5. Which FLT3 inhibitor fits my treatment setting and exact mutation?
  6. Is allogeneic transplant recommended in first remission, and how does MRD affect that advice?
  7. Will FLT3 be retested at relapse or before a new targeted treatment?
  8. What heart, liver, infection, differentiation-syndrome, and drug-interaction monitoring is required?

Report fever, breathing difficulty, rapid weight gain, swelling, dizziness, fainting, severe diarrhea, jaundice, or new neurologic symptoms promptly during treatment. Differentiation syndrome can cause fever, low blood pressure, lung infiltrates, fluid retention, kidney dysfunction, and rapid deterioration; early recognition and corticosteroid treatment can be lifesaving.

Keep copies of each molecular report with the specimen date. AML genetics can change, so label reports clearly as diagnosis, remission, refractory disease, or relapse. A result from years earlier should not be assumed to describe current leukemia.

A complete plan should state the induction or salvage regimen, whether a transplant search is underway, which marker will be used for MRD, and when repeat molecular testing is expected. FLT3 testing has the greatest value when it is fast enough to guide treatment and sensitive enough for the clinical question being asked.

References

Disclaimer

This article is educational and does not replace diagnosis or treatment by a hematologist. FLT3-directed therapy, transplant, and measurable residual disease testing must be selected for the exact mutation, AML genetics, treatment phase, and patient health. Fever, breathing difficulty, bleeding, or other severe symptoms during AML treatment require urgent medical attention.

RELATED ARTICLESMORE FROM AUTHOR